Maiullari E, Bianco E R, Cortese M G, Magro P, Guanà R, Vinardi S, Canavese F
Ospedale Infantile Regina Margherita, Torino, Italia.
Minerva Pediatr. 2008 Aug;60(4):407-10.
Macrogol 4,000 is one of the new generation's osmotic laxatives. It is constituted by a heavy molecular weight polymer without additional salts. In most of patients Macrogol 4,000 shows its efficacy in 48 hours from the beginning of treatment. Daily evacuations has been reported after first week therapy with an improvement in quality of life. The aim of this observational study was to demonstrate the efficacy of Macrogol 4,000 in the treatment of constipation in children.
The effect of Macrogol 4,000 was assessed in 120 children affected by constipation treated with therapeutic doses of Macrogol 4,000. The study period ranged from September 2006 to March 2007. The data analysis was collected with the evaluations concerning clinical examination and the consultation of daily diaries assembled by parents, tracking stooling pattern; in case of loosing contacts with the patient, a telephonic survey has been carried out. The child with symptoms improvement, i.e. reduction of the pain during defecation, daily spontaneous evacuations and better stool consistence, were considered ''normal''.
Of the 120 patients, 89 returned to the clinical follow-up, while the remaining 31, who missed the follow-up, has been contacted by telephone. To the final analysis, 103 patients (85.8%) have had a normalization of the clinical symptoms, 9 patients (7.5%) have refused Macrogol 4,000 for the unpleasant flavour, 8 patients (6.7%) did not have any improvement from the treatment.
The results of this observational study suggest that Macrogol 4,000 could be very useful to treat pediatric patients with constipation, also those affected by neuronal intestinal displasia (NID) type B.
聚乙二醇4000是新一代渗透性泻药之一。它由高分子量聚合物构成，无附加盐类。在大多数患者中，聚乙二醇4000在治疗开始后48小时内显示出疗效。据报道，在第一周治疗后每日排便情况有所改善，生活质量也得到提高。本观察性研究的目的是证明聚乙二醇4000治疗儿童便秘的疗效。
对120例接受聚乙二醇4000治疗剂量治疗的便秘儿童评估聚乙二醇4000的效果。研究期为2006年9月至2007年3月。通过临床检查评估及家长填写的每日排便日记收集数据分析，记录排便模式；若与患者失去联系，则进行电话调查。症状改善的儿童，即排便时疼痛减轻、每日自主排便且大便质地改善，被视为“正常”。
120例患者中，89例返回临床随访，其余31例失访患者通过电话联系。最终分析显示，103例患者（85.8%）临床症状恢复正常，9例患者（7.5%）因味道不佳拒绝使用聚乙二醇4000，8例患者（6.7%）治疗后无任何改善。
本观察性研究结果表明，聚乙二醇4000对治疗小儿便秘可能非常有用，包括那些患有B型神经元性肠发育异常（NID）的患儿。
